Inventor · disambiguated record
Kelly Frye
Also filed as: FRYE KELLY
24 granted patents·8 pending applications·1,347 citations·filing 2006–2025
98Inventor score
Top patents by PatentIndex Score
32 records- 0199US11084865B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2020·Granted Aug 10, 2021·14 cites·64 claims
- 0299US10464992B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Nov 5, 2019·60 cites·18 claims
- 0399US10406226B2Method of manufacturing VEGF antagonist fusion proteinsREGENERON PHARMA·Filed 2017·Granted Sep 10, 2019·70 cites·4 claims
- 0499US10400025B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Sep 3, 2019·54 cites·15 claims
- 0599US9914763B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Mar 13, 2018·56 cites·12 claims
- 0699US9636400B2VEGF specific fusion protein antagonist formulationsREGENERON PHARMA·Filed 2016·Granted May 2, 2017·59 cites·27 claims
- 0799US9580489B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Feb 28, 2017·67 cites·29 claims
- 0899US9340594B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2014·Granted May 17, 2016·73 cites·12 claims
- 0999US8802107B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2013·Granted Aug 12, 2014·65 cites·18 claims
- 1099US7807164B2Lyophilized VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2009·Granted Oct 5, 2010·83 cites·9 claims
- 1198US11066458B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2019·Granted Jul 20, 2021·12 cites·66 claims
- 1298US10857231B2Formulations of VEG antagonist fusion proteins and method of manufacturing themREGENERON PHARMA·Filed 2019·Granted Dec 8, 2020·9 cites·114 claims
- 1398US9511140B2Stable VEGF antagonist formulationsREGENERON PHARMA·Filed 2016·Granted Dec 6, 2016·62 cites·8 claims
- 1498US9416167B2Stable liquid formulations of dimer VEGF antagonistsREGENERON PHARMA·Filed 2014·Granted Aug 16, 2016·62 cites·8 claims
- 1598US8921316B2Stable liquid VEGF antagonist formulationsREGENERON PHARMA·Filed 2013·Granted Dec 30, 2014·62 cites·2 claims
- 1698US8710004B2Stable liquid VEGF antagonist formulationsDIX DANIEL·Filed 2012·Granted Apr 29, 2014·60 cites·6 claims
- 1798US8481046B2VEGF antagonist formulations for intravitreal administrationFURFINE ERIC·Filed 2011·Granted Jul 9, 2013·72 cites·9 claims
- 1898US8404638B2Dimer VEGF antagonist formulationsDIX DANIEL·Filed 2012·Granted Mar 26, 2013·62 cites·8 claims
- 1998US8110546B2VEGF antagonist formulationsDIX DANIEL·Filed 2010·Granted Feb 7, 2012·75 cites·5 claims
- 2098US8092803B2VEGF antagonist formulations for intravitreal administrationFURFINE ERIC·Filed 2010·Granted Jan 10, 2012·136 cites·19 claims
- 2197US11732024B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2021·Granted Aug 22, 2023·2 cites·60 claims
- 2297US7608261B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMACUTICALS INC·Filed 2007·Granted Oct 27, 2009·131 cites·17 claims
- 2395US12331099B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2024·Granted Jun 17, 2025·0 cites·30 claims
- 2490US11806398B2Citrate buffered VEGF antagonist formulationsREGENERON PHARMA·Filed 2020·Granted Nov 7, 2023·1 cites·28 claims
- 2590US2023374108A1Vegf antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2687US2025257118A1Vegf antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2780US2021252147A1VEGF Antagonist FormulationsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2880US2021393530A1VEGF Antagonist FormulationsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2980US2021252105A1VEGF Antagonist FormulationsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3080US2021393778A1VEGF Antagonist FormulationsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3167US2017073407A1Vegf antagonist formulationsREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 3262US2006217311A1VEGF antagonist formulationsDIX DANIEL·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kelly Frye files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →